Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: April 2013

Chapter 7 - Drug withdrawal syndromes in psychiatric patients in the emergency department

from Section 2. - Evaluation of the psychiatric patient


1. KesslerRC, BerglundP, DemlerO, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.Arch Gen Psychiatry 2005; 62:593–602.
2. KavanaghDJ, WaghornG, JennerL, et al. Demographic and clinical correlates of comorbid drug use disorders in psychosis: multivariate analyses from an epidemiological sample.Schizophr Res 2004;66:115–24.
3. RegierDA, FarmerME, RaeDS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–18.
4. SharpMJ, GetzJG. Self-process in comorbid mental illness and drug abuse. Am J Orthopsychiatry 1998;68:639–44.
5. RachBeiselJ, ScottJ, DixonL. Co-occurring severe mental illness and substance use disorders: a review of recent research.Psychiatric Serv 1999;50:1427–34.
6. KostenTR, O’ConnorPG. Management of drug and alcohol withdrawal.N Engl J Med 2003;348:1786–95.
7. JenkinsDH. Substance abuse and withdrawal in the intensive care unit. Surg Clin North Am 2000;80:1033–53.
8. OlmedoR, HoffmanRS. Withdrawal syndromes. Emerg Med Clin North Am 2000;18:273–85.
9. SwiftRM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482–90.
10. BourgeoisJA, NelsonJL, SlackMB, et al. Comorbid affective disorders and personality traits in alcohol abuse inpatients at an Air Force Medical Center. Mil Med 1999;164:103–6.
11. D’Onofrio G, RathlevNK, UlrichAS, et al. Lorazepam for the prevention of recurrent seizures related to alcohol. N Engl J Med 1999;340:915–19.
12. ChanceJF. Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med 1991;20:520–2.
13. RathlevNK, D’Onofrio G, FishSS, et al. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures.Ann Emerg Med 1994;23:513–18.
14. EarnestMP, FeldmanH, MarxJA, et al. Intracranial lesions shown by CT scans in 259 cases of first alcohol related seizures. Neurology 1988;38:1561–5.
15. SchuckitMA, TippJE, ReichT, et al. The histories of withdrawal convulsions and delirium tremens in1648 alcohol dependent subjects. Addiction 1995;90:1335–47.
16. FergusonJA, SuelzerCJ, EckertGJ, et al. Risk factors for delirium tremens development. J Gen Intern Med 1996;11:410–14.
17. HolbrookAM, CrowtherR, LotterA, et al. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 1999;160:649–55.
18. AdamsF, DernandezF, AndesonBS. Emergency pharmacotherapy of delirium in the critically ill cancer patient. Psychosomatics 1986;13:56–60.
19. Mayo-SmithMF.Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline.JAMA 1997;278:144–51.
20. AmatoL, MinozziS, VecchiS, et al. Benzodiazepines for alcohol withdrawal.Cochrane Database Syst Rev 2010;3:CD005063. DOI: 10.1002/14651858.CD005063.pub3.
21. Mayo-Smith, BeecherLH, FischerTL, et al. Management of alcohol withdrawal delirium. An evidenced-based practice guideline. Arch Intern Med 2004;164:1405–12.
22. ThomasDW, FreedmanDX. Treatment of the alcohol withdrawal syndrome: comparison of promazine and paraldehyde. JAMA 1964;188:244–6.
23. ChambersJF, SchultzJD. Double-blind study of three drugs in the treatment of acute alcoholic states. Q J Stud Alcohol 1965;26:10–18.
24. SerenyG, KalantH. Comparative clinical evaluation of chlordiazepoxide and promazine in treatment of alcohol-withdrawal syndrome. BMJ 1965;1:92–7.
25. Mayo-Smith, BeecherLH, FischerTL, et al. Management of Alcohol Withdrawal Delirium. An evidenced-based practice guideline. Arch Intern Med 2004;164:1405–12.
26. DaeppanJB, GacheP, LandryU, et al. Symptom-triggered vs. fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002;162:117–21.
27. HeckselKA, BostwickJM, JaegerTM, ChaSS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. Mayo Clin Proc 2008;83:274–9.
28. SaitzR, Mayo-SmithMF, RobertsMS, et al. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. JAMA 1994;272:519–23.
29. HackJB, HoffmanRS, NelsonLS. Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early?J Med Toxicol 2006;2:55–60.
30. McCowanC, MarikP. Refractory delirium tremens treated with propofol: a case series. Crit Care Med 2000;28:1781–4.
31. NolopKB, NatowA. Unprecedented sedative requirement during delirium tremens. Crit Care Med 1985;13:246–7.
32. DeBellisR, SmithBS, ChoiS, et al. Management of delirium tremens. J Intensive Care Med 2005;20:164–73.
33. LannMA, MolinaDK. A fatal case of benzodiazepine withdrawal. Am J Forensic Med Pathol 2009;30:177–9.
34. MollerHJ. Effectiveness and safety of benzodiazepines, benzodiazepine dependence and withdrawal: myths and management. J Clin Psychopharmacol 1999;19:115–25.
35. VoshaarRC, CouveeJE, van BalkomAJ, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis.Br J Psychiatry 2006;189:213–20.
36. LeTourneauJL, HaggDS, SmithSM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocritical Care 2008;8:430–3.
37. WojtowiczJM, YaremaMC, WaxPM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. Can J Emerg Med Care 2008;10:69–74.
38. PerezE, ChuJ, BaniaT. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal.Ann Emerg Med 2006;48:219–20.
39. PalmerRB. Gamma-Butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate. Toxicol Rev 2004;23:21–31.
40. Drug-Related Emergency Department Visits. DAWN Series D-28, DHHS Publication No. (SMA) 06–4143, Rockville, MD; 2006.